ASCPT Task Force for Advancing Pharmacometrics and Integration into Drug Development

被引:6
|
作者
Goldberger, M. J. [2 ]
Singh, N. [3 ]
Allerheiligan, S. [4 ]
Gobburu, J. V. S. [1 ]
Lalonde, R. [5 ]
Smith, B. [6 ]
Ryder, S. [7 ]
Yozviak, A. [3 ]
机构
[1] US FDA, Div Pharmacometr, Off Clin Pharmacol, Silver Spring, MD USA
[2] Abbott, Rockville, MD USA
[3] McKinsey & Co Inc, New York, NY USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Pfizer Global Res & Dev, New London, CT USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
[7] Astellas Pharma Global Dev, Deerfield, IL USA
关键词
LABELING DECISIONS; IMPACT; PHARMACOLOGY; EXPERIENCE; APPROVAL;
D O I
10.1038/clpt.2010.141
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Traditionally, medical and biostatistical experts have played a central role in ensuring validity of pharmaceutical testing. The science of pharmacometrics provides powerful approaches for supporting important drug development and regulatory decisions. Numerous case studies published by academic, industry, and US Food and Drug Administration scientists attest to the significant contribution of pharmacometrics to decision making. The economic and public health benefits of applying this discipline to clinical trials far outweigh the cost associated with its implementation. The purpose of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Task Force is to build on the momentum and accelerate dissemination of its impact and adoption into drug development. We describe briefly the contributions of pharmacometrics and the specific goals of the Task Force.
引用
收藏
页码:158 / 161
页数:5
相关论文
共 50 条
  • [1] ASCPTTask Force for Advancing Pharmacometrics and Integration Into Drug Development (vol 88, pg 158, 2010)
    Goldberger, M. J.
    Singh, N.
    Allerheiligen, S.
    Gobburu, J. V. S.
    Lalonde, R.
    Smith, B.
    Ryder, S.
    Yozviak, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (06) : 883 - 883
  • [2] Task force refreshes ASCPT strategic plan
    不详
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 622 - 622
  • [4] Quantitative Decision Making in Drug Development: Pharmacometrics
    Suzuki, Akiyuki
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2016, 136 (04): : 537 - 542
  • [5] AIDS DRUG DEVELOPMENT - TASK-FORCE TO SPEED DRUG PIPELINE
    COHEN, J
    [J]. SCIENCE, 1993, 262 (5140) : 1641 - 1641
  • [6] Pharmacometrics-guided drug development of antihyperhidrosis agents
    Mehrotra, Shailly
    Schmith, Virginia D.
    Dumitrescu, Teodora Pene
    Gobburu, Jogarao
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (11): : 1256 - 1267
  • [7] Antibacterial drug development to be supported by US FDA task force
    Leeson, Natasha
    [J]. FUTURE MICROBIOLOGY, 2012, 7 (12) : 1347 - 1347
  • [8] Advancing the Methods of the US Preventive Services Task Force
    Krist, Alex H.
    Bibbins-Domingo, Kirsten
    Wolff, Tracy A.
    Mabry-Hernandez, Iris R.
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2018, 54 (01) : S1 - S3
  • [9] Application of Pharmacometrics in Advancing the Clinical Research of Antibody-Drug Conjugates: Principles and Modeling Strategies
    Li, Xiuqi
    Liu, Dan
    Liu, Shupeng
    Yu, Mengyang
    Wu, Xiaofei
    Wang, Hongyun
    [J]. CLINICAL PHARMACOKINETICS, 2024,
  • [10] Biostatistics and Pharmacometrics: Quantitative Sciences to Propel Drug Development Forward
    Smith, B. P.
    Vincent, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (02) : 141 - 144